CR20180115A - Composiciones biofarmacéuticas - Google Patents

Composiciones biofarmacéuticas

Info

Publication number
CR20180115A
CR20180115A CR20180115A CR20180115A CR20180115A CR 20180115 A CR20180115 A CR 20180115A CR 20180115 A CR20180115 A CR 20180115A CR 20180115 A CR20180115 A CR 20180115A CR 20180115 A CR20180115 A CR 20180115A
Authority
CR
Costa Rica
Prior art keywords
compositions
biopharmaceutical compositions
biopharmaceutical
interleukin
present description
Prior art date
Application number
CR20180115A
Other languages
English (en)
Inventor
Narendra B Bam
Jennifer Dally
Myrna A Monck
Michelle Spatara
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56877084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20180115(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of CR20180115A publication Critical patent/CR20180115A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La presente descripción se refiere a composiciones, para tratar enfermedades mediadas por interleuquina 5 (IL-5), y métodos relacionados
CR20180115A 2015-08-24 2016-08-22 Composiciones biofarmacéuticas CR20180115A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562209000P 2015-08-24 2015-08-24
US201562240131P 2015-10-12 2015-10-12
US201562247906P 2015-10-29 2015-10-29
US201562249497P 2015-11-02 2015-11-02
PCT/IB2016/055012 WO2017033121A1 (en) 2015-08-24 2016-08-22 Biopharmaceutical compositions

Publications (1)

Publication Number Publication Date
CR20180115A true CR20180115A (es) 2018-04-12

Family

ID=56877084

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20180115A CR20180115A (es) 2015-08-24 2016-08-22 Composiciones biofarmacéuticas

Country Status (22)

Country Link
US (7) US10870695B2 (es)
EP (2) EP3341409A1 (es)
JP (3) JP6821659B2 (es)
KR (1) KR20180037275A (es)
CN (5) CN108137683A (es)
AU (1) AU2016311385C1 (es)
BR (1) BR112018003741A2 (es)
CA (1) CA2996088A1 (es)
CL (1) CL2018000499A1 (es)
CO (1) CO2018001840A2 (es)
CR (1) CR20180115A (es)
DO (1) DOP2018000057A (es)
EA (1) EA037487B1 (es)
IL (1) IL257539A (es)
MA (1) MA42692A (es)
MX (1) MX2018002319A (es)
PE (1) PE20181176A1 (es)
PH (1) PH12018500379A1 (es)
TW (2) TWI750133B (es)
UY (1) UY36868A (es)
WO (1) WO2017033121A1 (es)
ZA (1) ZA201801158B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108137683A (zh) 2015-08-24 2018-06-08 葛兰素史密斯克莱知识产权（第2 号）有限公司 生物医药组合物
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
US11111292B2 (en) 2016-12-23 2021-09-07 Cephalon, Inc. Anti-IL-5 antibodies
PE20191844A1 (es) * 2017-05-26 2019-12-31 Glaxosmithkline Ip Dev Ltd Composiciones biofarmaceuticas y metodos relacionados
CA3064859A1 (en) 2017-06-06 2018-12-13 Glaxosmithkline Llc Biopharmaceutical compositions and methods for pediatric patients
EP3689906A4 (en) 2017-09-29 2021-04-07 Jiangsu Hengrui Medicine Co., Ltd. IL-5 ANTIBODIES, ANTIGIBINDING FRAGMENT THEREOF, AND MEDICAL USES THEREOF
US11613571B2 (en) 2018-05-23 2023-03-28 Glaxosmithkline Intellectual Property Development Limited Biopharmaceutical compositions comprising antibody variants
US20220144937A1 (en) 2019-03-29 2022-05-12 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing antibody against il-5 and use thereof
CN115298218A (zh) * 2019-12-18 2022-11-04 特沙诺有限公司 生物药物组合物和相关方法
CA3232203A1 (en) * 2021-09-22 2023-03-30 James MATTHAEI Il5ra cell surface markers

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ249633A (en) 1992-02-06 1995-12-21 Schering Corp Monoclonal and humanised antibodies to interleukin-5, their production, use and methods for producing humanised antibodies.
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US6056957A (en) 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
US5783184A (en) 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5693323A (en) 1994-12-23 1997-12-02 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
WO1996021000A2 (en) 1994-12-23 1996-07-11 Smithkline Beecham Corporation Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders
GB9712410D0 (en) 1997-06-14 1997-08-13 Glaxo Group Ltd Peptides and compounds that bind to the il-5 receptor
EP1739078A1 (de) 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
WO2007100902A2 (en) 2006-02-28 2007-09-07 Oligasis Corporation Acryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation
EP2777710A1 (en) 2007-04-30 2014-09-17 Glaxosmithkline LLC Methods for administering anti-IL-5 antibodies
JP5490714B2 (ja) 2007-11-28 2014-05-14 メディミューン，エルエルシー タンパク質製剤
CA2706419A1 (en) * 2007-11-30 2009-06-04 Glaxo Group Limited Antigen-binding constructs binding il-13
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
EA201071137A1 (ru) 2008-03-28 2011-04-29 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Способы лечения
FR2944448B1 (fr) 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
JP5657224B2 (ja) 2009-08-31 2015-01-21 富士フイルム株式会社 放射線画像検出器の撮像面の設置誤差の程度を判定する方法および装置
FR2958646B1 (fr) 2010-04-07 2012-05-18 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive d'acide hydrophobe.
US20120301478A1 (en) 2010-01-14 2012-11-29 Yuichiro Ogura Pharmaceutical for Preventing or Treating Disorders Accompanied by Ocular Angiogenesis and/or Elevated Ocular Vascular Permeability
AU2012214419B2 (en) 2011-02-09 2015-12-24 Glaxosmithkline Llc Lyophilized formulations
JP2014510152A (ja) 2011-04-07 2014-04-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 粘度が低減された処方物
KR20140018966A (ko) 2011-04-07 2014-02-13 글락소스미스클라인 엘엘씨 점도가 감소된 제제
EP2738172A1 (en) 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
CA2899308C (en) * 2013-03-14 2017-04-18 Abbvie Inc. Low acidic species adalimumab compositions and uses thereof
WO2014141149A1 (en) 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Formulations with reduced viscosity
EP2848615A1 (en) 2013-07-03 2015-03-18 Almirall, S.A. New pyrazole derivatives as CRAC channel modulators
WO2015049519A2 (en) 2013-10-02 2015-04-09 Vectura Limited Method and apparatus
EP3738981A1 (en) 2014-01-24 2020-11-18 NGM Biopharmaceuticals, Inc. Antibodies binding beta klotho domain 2 and methods of use thereof
CN113388032A (zh) 2014-02-06 2021-09-14 X4制药(奥地利)有限责任公司 大肠杆菌特异性抗体序列
TW201705961A (zh) 2015-06-11 2017-02-16 阿爾米雷爾有限公司 作為ｊａｋ抑制劑的２－（吡唑并吡啶－３－基）嘧啶衍生物
CN108137683A (zh) 2015-08-24 2018-06-08 葛兰素史密斯克莱知识产权（第2 号）有限公司 生物医药组合物

Also Published As

Publication number Publication date
AU2016311385A1 (en) 2018-03-15
AU2016311385B2 (en) 2019-05-09
EA201890572A1 (ru) 2018-10-31
EP3341409A1 (en) 2018-07-04
WO2017033121A1 (en) 2017-03-02
ZA201801158B (en) 2019-08-28
CO2018001840A2 (es) 2018-05-31
JP6821659B2 (ja) 2021-01-27
IL257539A (en) 2018-04-30
EP4056590A1 (en) 2022-09-14
PE20181176A1 (es) 2018-07-20
AU2016311385C1 (en) 2019-08-22
TW202233238A (zh) 2022-09-01
CN116327923A (zh) 2023-06-27
MA42692A (fr) 2018-07-04
DOP2018000057A (es) 2018-03-15
JP2022023049A (ja) 2022-02-07
KR20180037275A (ko) 2018-04-11
US20220185878A1 (en) 2022-06-16
EA037487B1 (ru) 2021-04-02
US20180251539A1 (en) 2018-09-06
UY36868A (es) 2017-03-31
US11286298B2 (en) 2022-03-29
MX2018002319A (es) 2018-04-11
JP7463070B2 (ja) 2024-04-08
CN116327922A (zh) 2023-06-27
CN108137683A (zh) 2018-06-08
US20220380452A1 (en) 2022-12-01
PH12018500379A1 (en) 2018-09-03
BR112018003741A2 (pt) 2018-09-25
CN116474091A (zh) 2023-07-25
TWI780988B (zh) 2022-10-11
US11274148B2 (en) 2022-03-15
US11299541B2 (en) 2022-04-12
US11459384B2 (en) 2022-10-04
TW201722473A (zh) 2017-07-01
US20210340247A1 (en) 2021-11-04
CN116327921A (zh) 2023-06-27
US20200199219A1 (en) 2020-06-25
US10870695B2 (en) 2020-12-22
CA2996088A1 (en) 2017-03-02
TWI750133B (zh) 2021-12-21
US20210332125A1 (en) 2021-10-28
JP2020033351A (ja) 2020-03-05
US20210340246A1 (en) 2021-11-04
JP2018526369A (ja) 2018-09-13
CL2018000499A1 (es) 2018-07-06

Similar Documents

Publication Publication Date Title
DOP2018000057A (es) Composiciones biofarmacéuticas
CL2016002455A1 (es) Anticuerpos multiespecíficos.
CO2018000648A2 (es) Compuestos de piridina sustituidos, intermediarios para su preparación y composiciones que los comprenden
CO2017001884A2 (es) Polimorfos de selinexor
BR112017025004A2 (pt) composições compreendendo cepas bacterianas
BR112017003414A2 (pt) composições compreendendo caseína e métodos para produzir as mesmas
BR112016008685A2 (pt) Gene para indução de partenogênese, componente de reprodução apomítica
BR112017000456A2 (pt) composições antivirais tópicas e métodos de uso das mesmas
UY36287A (es) COMPUESTO DE OBJETIVO A IL-23A y TNF-ALFA Y USO DEL MISMO
BR112017013498A2 (pt) composições de inibidor de nitrificação e métodos para a preparação das mesmas
BR112018003526A2 (pt) métodos de tratamento de doenças inflamatórias
MX2016003892A (es) Uso de dihidrooxindolilsulfonamidas sustituidas, o sus sales, para aumentar la tolerancia de plantas al estres.
CL2017000312A1 (es) Elección de microarn como diana para trastornos metabólicos
BR112017005109A2 (pt) produto refratário com base em al2o3, composição de matérias-primas para a fabricação do produto, método para a fabricação de um produto refratário, produto refratário, e emprego do produto refratário
BR112017009289A2 (pt) métodos de administrar composições de amantadina
BR112016030129A2 (pt) Composição, artigo moldado por injeção e processo para produzir um artigo moldado por injeção
MX2016013308A (es) Uso de oxotetrahidroquinolinilsulfonamidas sustituidas o sus sales para aumentar la tolerancia al estres en plantas.
BR112018003800A2 (pt) derivados de 1,7-diaril-1,6-heptadieno-3,5-diona, processo para a sua produção e utilização
BR112017025427A2 (pt) composição farmacêutica oral
CL2017002255A1 (es) Procesos para preparar fluorocetólidos.
MX2017003550A (es) Uso de cisteamina en tratamiento de infecciones causadas por levaduras/mohos.
UY36173A (es) Metodo de tratamiento de enfermedades relacionadas con el factor inducible por hipoxia
CL2018002149A1 (es) Proceso.
BR112019002729A2 (pt) composição farmacêutica sólida e processo para preparar uma composição farmacêutica sólida
BR112016023767A2 (pt) forma sólida, composição farmacêutica, compostos, métodos, composições e utilizações